BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November. He will discuss the results of the recently completed Phase 1b study of YTX-7739 in patients with Parkinson’s disease and the development strategy going forward.
| Event: | Stifel Healthcare Conference 2021 |
| Presentation: | Virtual live webcast |
| Date: | Wednesday, November 17 |
| Time: | 9:20 a.m. EST |
| Webcast: | Events section of the Yumanity website |
| Event: | Jefferies London Healthcare Conference |
| Presentation: | Virtual on-demand webcast |
| Date: | November 16 to 18 |
| Time: | Thursday, November 18 at 3:00 a.m. EST |
| Webcast: | Events section of the Yumanity website |
| Event: | Piper Sandler Annual Healthcare Conference |
| Presentation: | Virtual on-demand webcast |
| Date: | November 30 to December 2 |
| Time: | Monday, November 22 at 10:00 a.m. EST |
| Webcast: | Events section of the Yumanity website |
An audio webcast of each presentation can be accessed through the Events section of the Company's website at yumanity.com/investor-relations/events-presentations. An archived replay of each webcast will also be available on the Company's website.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is in clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.
Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006
Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006
